The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Open accessAbstract
BACKGROUND: Many patients with an exacerbation of chronic obstructive pulmonary disease (COPD) are treated with antibiotics. However, the value of antibiotics remains uncertain as systematic reviews and clinical trials have shown conflicting results. OBJECTIVES: To assess the effects of antibiotics in the management of acute COPD exacerbations on treatment failure as observed between seven days and one month after treatment initiation (primary outcome) and on other patient-important outcomes (mortality, adverse events, length of hospital stay). SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and other electronically available databases up to September 2012. SELECTION CRITERIA: Randomised controlled trials (RCTs) in people with acute COPD exacerbations comparing antibiotic therapy and placebo with a follow-up of at least seven days. DATA COLLECTION AND ANALYSIS: Two review authors independently screened references and extracted data from trial reports. We kept the three groups of outpatients, inpatients and patients admitted to the intensive care unit (ICU) separate for benefit outcomes and mortality because we considered them to be clinically too different to be summarised in one group. We considered outpatients to have a mild to moderate exacerbation, inpatients to have a severe exacerbation and ICU patients to have a very severe exacerbation. Where outcomes or study details were not reported we requested missing data from the authors of the primary studies. We calculated pooled risk ratios (RR) for treatment failure, Peto odds ratios (OR) for rare events (mortality and adverse events) and weighted mean differences (MD) for continuous outcomes using fixed-effect models. We used GRADE to assess the quality of the evidence. MAIN RESULTS: Sixteen trials with 2068 participants were included. In outpatients (mild to moderate exacerbations), there was evidence of low quality that antibiotics did statistically significantly reduce the risk for treatment failure between seven days and one month after treatment initiation (RR 0.75; 95% CI 0.60 to 0.94; I(2) = 35%) but they did not significantly reduce the risk when the meta-analysis was restricted to currently available drugs (RR 0.80; 95% CI 0.63 to 1.01; I(2) = 33%). Evidence of high quality showed that antibiotics statistically significantly reduced the risk of treatment failure in inpatients with severe exacerbations (ICU not included) (RR 0.77; 95% CI 0.65 to 0.91; I(2) = 47%) regardless of whether restricted to current drugs. The only trial with 93 patients admitted to the ICU showed a large and statistically significant effect on treatment failure (RR 0.19; 95% CI 0.08 to 0.45; high-quality evidence).Evidence of low-quality from four trials in inpatients showed no effect of antibiotics on mortality (Peto OR 1.02; 95% CI 0.37 to 2.79). High-quality evidence from one trial showed a statistically significant effect on mortality in ICU patients (Peto OR 0.21; 95% CI 0.06 to 0.72). Length of hospital stay (in days) was similar in the antibiotics and placebo groups except for the ICU study where antibiotics statistically significantly reduced length of hospital stay (mean difference -9.60 days; 95% CI -12.84 to -6.36 days). One trial showed no effect of antibiotics on re-exacerbations between two and six weeks after treatment initiation. Only one trial (N = 35) reported health-related quality of life but did not show a statistically significant difference between the treatment and control group.Evidence of moderate quality showed that the overall incidence of adverse events was higher in the antibiotics groups (Peto OR 1.53; 95% CI 1.03 to 2.27). Patients treated with antibiotics experienced statistically significantly more diarrhoea based on three trials (Peto OR 2.62; 95% CI 1.11 to 6.17; high-quality evidence). AUTHORS' CONCLUSIONS: Antibiotics for COPD exacerbations showed large and consistent beneficial effects across outcomes of patients admitted to an ICU. However, for outpatients and inpatients the results were inconsistent. The risk for treatment failure was significantly reduced in both inpatients and outpatients when all trials (1957 to 2012) were included but not when the analysis for outpatients was restricted to currently used antibiotics. Also, antibiotics had no statistically significant effect on mortality and length of hospital stay in inpatients and almost no data on patient-reported outcomes exist. These inconsistent effects call for research into clinical signs and biomarkers that help identify patients who benefit from antibiotics and patients who experience no effect, and in whom downsides of antibiotics (side effects, costs and multi-resistance) could be avoided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Ram, F. S., Rodriguez-Roisin, R., Granados-Navarrete, A., Garcia-Aymerich, J., & Barnes, N. C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004403.pub2 · Cited by 170
Self-citationRetractedProphylactic antibiotic therapy for chronic bronchitis
Staykova, T., Black, P., Chacko, E., & Poole, P. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004105 · Cited by 86
RetractedGRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Celli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A., Chavannes, N., Dillard, T., Fahy, B., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,421
Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease
ANTHONISEN, N. R., MANFREDA, J., WARREN, C. P. W., HERSHFIELD, E. S., HARDING, G. K. M., & NELSON, N. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-2-196 · Cited by 2,492
Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., McCormick, M., Haldar, K., Kebadze, T., Duvoix, A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201104-0597oc · Cited by 1,094
SEEMUNGAL, T., HARPER-OWEN, R., BHOWMIK, A., MORIC, I., SANDERSON, G., MESSAGE, S., MacCALLUM, P., MEADE, T. W., JEFFRIES, D. J., JOHNSTON, S. L., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2105011 · Cited by 1,018
Toward a Consensus Definition for COPD Exacerbations
Rodriguez-Roisin, R. (2000) · Chest · doi:10.1378/chest.117.5_suppl_2.398s · Cited by 969
Wedzicha, W. (2004) · Thorax · doi:10.1136/thx.2003.awjan · Cited by 777
Patel, I. S. (2002) · Thorax · doi:10.1136/thorax.57.9.759 · Cited by 690
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
COPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease
Sethi, S., & Murphy, T. F. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800353 · Cited by 1,234
Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., McCormick, M., Haldar, K., Kebadze, T., Duvoix, A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201104-0597oc · Cited by 1,094
Chronic obstructive pulmonary disease
Decramer, M., Janssens, W., & Miravitlles, M. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60968-9 · Cited by 972
Guidelines for the management of adult lower respiratory tract infections - Full version
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03672.x · Cited by 942
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
Wedzicha, J. A., Miravitlles, M., Hurst, J. R., Calverley, P. M. A., Albert, R. K., Anzueto, A., Criner, G. J., Papi, A., Rabe, K. F., Rigau, D., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00791-2016 · Cited by 683
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Antibiotic Treatment of Exacerbations of COPD
Stolz, D., Christ-Crain, M., Bingisser, R., Leuppi, J., Miedinger, D., Müller, C., Huber, P., Müller, B., & Tamm, M. (2007) · Chest · doi:10.1378/chest.06-1500 · Cited by 521
The role of the microbiome in exacerbations of chronic lung diseases
Dickson, R. P., Martinez, F. J., & Huffnagle, G. B. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61136-3 · Cited by 495
Guidelines for the management of adult lower respiratory tract infections - Summary
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03602.x · Cited by 468
COPD Guidelines: A Review of the 2018 GOLD Report
Mirza, S., Clay, R. D., Koslow, M. A., & Scanlon, P. D. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.05.026 · Cited by 444
The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease
O’Dwyer, D. N., Dickson, R. P., & Moore, B. B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600279 · Cited by 362
MacLeod, M., Papi, A., Contoli, M., Beghé, B., Celli, B. R., Wedzicha, J. A., & Fabbri, L. M. (2021) · Respirology · doi:10.1111/resp.14041 · Cited by 359
Ko, F. W., Chan, K. P., Hui, D. S., Goddard, J. R., Shaw, J. G., Reid, D. W., & Yang, I. A. (2016) · Respirology · doi:10.1111/resp.12780 · Cited by 354
Vogelmeier, C. F., Criner, G. J., Martínez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.02.001 · Cited by 309
C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations
Butler, C. C., Gillespie, D., White, P., Bates, J., Lowe, R., Thomas-Jones, E., Wootton, M., Hood, K., Phillips, R., Melbye, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803185 · Cited by 277
Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond
May, S. M., & Li, J. T. C. (2015) · Allergy and Asthma Proceedings · doi:10.2500/aap.2015.36.3812 · Cited by 273
Empirical Evaluation of Very Large Treatment Effects of Medical Interventions
Pereira, T. V., Horwitz, R. I., & Ioannidis, J. P. A. (2012) · JAMA · doi:10.1001/jama.2012.13444 · Cited by 257
Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review
Riley, C. M., & Sciurba, F. C. (2019) · JAMA · doi:10.1001/jama.2019.0131 · Cited by 258
Amatya, Y., Rupp, J., Russell, F. M., Saunders, J., Bales, B., & House, D. R. (2018) · International Journal of Emergency Medicine · doi:10.1186/s12245-018-0170-2 · Cited by 137
“benefit from antibiotic use in acute exacerbations [25].”
BackgroundAntibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit
López-Campos, J. L., Hartl, S., Pozo-Rodriguez, F., Roberts, C. M., & on behalf of the European COPD Audit team (2015) · PLOS ONE · doi:10.1371/journal.pone.0124374 · Cited by 59
Puhan, M. A., Vollenweider, D., Steurer, J., Bossuyt, P. M., & ter Riet, G. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-28 · Cited by 38
Self-citationFulton, A. S., Hill, A. M., Williams, M. T., Howe, P. R. C., & Coates, A. M. (2015) · Nutrition Reviews · doi:10.1093/nutrit/nuv017 · Cited by 26
Metadata
- Authors
- Vollenweider, D. J., Jarrett, H., Steurer-Stey, C. A., Garcia-Aymerich, J., & Puhan, M. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-12-12
- Volume
- 10
- Pages
- CD010257-CD010257
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2123964203
- Cited by
- 425
- References
- 56
- FWCI
- 23.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.